Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.33 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.33 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.33 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25453058 | 0.76 | PARP1 (0.37) | PARP1KMT2AMEN1BRD4ABCC9 | |
| SCHEMBL21603397 | 0.74 | MEN1 (0.38) | KMT2AMEN1TSHRBRD4 | |
| SCHEMBL31391626 | 0.71 | MEN1 (0.39) | PARP1KMT2AMEN1BRD4ABCC9 | |
| SCHEMBL21608292 | 0.71 | PARP1 (0.40) | PARP1KMT2ATSHRBRD4 | |
| SCHEMBL29010819 | 0.71 | MEN1 (0.39) | PARP1KMT2AMEN1BRD4ABCC9 | |
| SCHEMBL29209082 | 0.69 | BRD4 (0.42) | PARP1KMT2AMEN1BRD4 | |
| SCHEMBL25463283 | 0.69 | PARP1 (0.41) | PARP1KMT2A | |
| SCHEMBL9400286 | 0.69 | ALDH1A1 (0.36) | KMT2AMEN1TSHR | |
| SCHEMBL24649692 | 0.68 | HTR2A (0.43) | PARP1KMT2AMEN1BRD4 | |
| SCHEMBL31543992 | 0.68 | BRD4 (0.41) | PARP1KMT2AMEN1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-09-09 | — | — | US | disclosed |
| WO-2019243535-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210277003-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | PARP1 345/4885KMT2A 1825/4885MEN1 3073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.